Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Conditions
Interventions
EP31670
Locations
6
United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
University of Washington/Fred Hutchinson Cancer Center
Seattle, Washington, United States
Start Date
December 21, 2022
Primary Completion Date
May 1, 2025
Completion Date
May 1, 2025
Last Updated
January 14, 2025
NCT04239157
NCT05372640
NCT05636514
NCT06859424
NCT06994676
NCT06523556
Lead Sponsor
Epigenetix, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions